Super-enhancer-associated MEIS1 Promotes Transcriptional Dysregulation in Ewing Sarcoma in Co-Operation with EWS-FLI1.
Lehang Lin,Moli Huang,Xianping Shi,Anand Mayakonda,Kaishun Hu,Yan-Yi Jiang,Xiao Guo,Li Chen,Brendan Pang,Ngan Doan,Jonathan W. Said,Jianjun Xie,Sigal Gery,Xu Cheng,Zhaoyu Lin,Jinsong Li,Benjamin P. Berman,Dong Yin,De-Chen Lin,H. Phillip Koeffler
DOI: https://doi.org/10.1093/nar/gky1207
IF: 14.9
2018-01-01
Nucleic Acids Research
Abstract:As the second most common malignant bone tumor in children and adolescents, Ewing sarcoma is initiated and exacerbated by a chimeric oncoprotein, most commonly, EWS-FLI1. In this study, we apply epigenomic analysis to characterize the transcription dysregulation in this cancer, focusing on the investigation of super-enhancer and its associated transcriptional regulatory mechanisms. We demonstrate that super-enhancer-associated transcripts are significantly enriched in EWS-FLI1 target genes, contribute to the aberrant transcriptional network of the disease, and mediate the exceptional sensitivity of Ewing sarcoma to transcriptional inhibition. Through integrative analysis, we identify MEIS1 as a super-enhancer-driven oncogene, which co-operates with EWS-FLI1 in transcriptional regulation, and plays a key pro-survival role in Ewing sarcoma. Moreover, APCDD1, another super-enhancer-associated gene, acting as a downstream target of both MEIS1 and EWS-FLI1, is also characterized as a novel tumor-promoting factor in this malignancy. These data delineate super-enhancer-mediated transcriptional deregulation in Ewing sarcoma, and uncover numerous candidate oncogenes which can be exploited for further understanding of the molecular pathogenesis for this disease.